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Objective: To investigate the cost effectiveness of management of patients within the context of a multidisciplinary
team (MDT) meeting in cancer and non-cancer teams in secondary care.
Design: Systematic review.
Data sources: EMBASE, MEDLINE, NHS EED, CINAHL, EconLit, Cochrane Library, and NHS HMIC.
Eligibility criteria for selecting studies: Randomised controlled trials (RCTs), cohort, case–control, before and after
and cross-sectional study designs including an economic evaluation of management decisions made in any disease in
secondary care within the context of an MDT meeting.
Data extraction: Two independent reviewers extracted data and assessed methodological quality using the
Consensus on Health Economic Criteria (CHEC-list). MDTs were defined by evidence of two characteristics: decision
making requiring a minimum of two disciplines; and regular meetings to discuss diagnosis, treatment and/or patient
management, occurring at a physical location or by teleconferencing. Studies that reported on the costs of
administering, preparing for, and attending MDT meetings and/or the subsequent direct medical costs of care,
non-medical costs, or indirect costs, and any health outcomes that were relevant to the disease being investigated
were included and classified as cancer or non-cancer MDTs.
Results: Fifteen studies (11 RCTs in non-cancer care, 2 cohort studies in cancer and non-cancer care, and 2 before and
after studies in cancer and non cancer care) were identified, all with a high risk of bias. Twelve papers reported the
frequency of meetings which varied from daily to three monthly and all reported the number of disciplines included
(mean 5, range 2 to 9). The results from all studies showed mixed effects; a high degree of heterogeneity prevented a
meta-analysis of findings; and none of the studies reported how the potential savings of MDT working may offset the
costs of administering, preparing for, and attending MDT meetings.
Conclusions: Current evidence is insufficient to determine whether MDT working is cost-effective or not in secondary
care. Further studies aimed at understanding the key aspects of MDT working that lead to cost-effective cancer and
non-cancer care are required.
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Multi-disciplinary teams (MDTs) are an integrated
approach to healthcare in which medical and allied
health professionals consider relevant treatment options
and collaboratively develop an individual treatment plan
for patients [1,2]. Despite some scepticism about the
effectiveness of MDT working in health care [2-4], the
concept of MDT working is now widely accepted [5]
and considered to be good practice in many parts of the
world for the successful management of chronic disease
[6-8]. Teamwork is recommended because of increasing
complexity in patient management and subspecialisation
of health professionals, and because of changes in working
patterns in the health care sector with reduced hours of
work [9].
Areas where MDT working is now commonly adopted
in secondary care include care of the elderly, heart
failure, stroke, mental health, and critical care. The area
that has seen the most increase in MDT working,
however, is in oncology where MDT working has been
widely recommended including in North America [10],
Australia [11,12], and continental Europe [13,14]. Indeed
it is now mandated as part of the NHS Cancer Plan in
the UK [6]. Studies have shown that MDT working in
cancer care is associated with decreased time from
diagnosis to treatment [15], more accurate pathological
staging of disease [16], increased number of patients
treated with radical intent [17,18], improved survival
[19], and greater patient satisfaction [20]. However,
these studies are largely retrospective, and there is a
lack of well designed randomised controlled trials and
prospective studies in this field [1,21-23]. There is
also a need to consider the costs of administering,
preparing for, and attending MDT meetings in any
evaluation.
MDTs demand considerable organisation, management
infrastructure and funding to ensure that the correct
personnel are present, that the relevant patient details are
collated, and that the pathological and radiological
materials are reviewed by the appropriate specialists
before and during the meeting [1,24,25]. Indeed, it has
been shown that if critical information is absent at the
MDT meeting, decisions may need to change following
the meeting and this can delay the start of treatment [26].
In the UK enormous investment has been made to
ensure the functioning of cancer MDT meetings and
it is estimated to cost the National Health Service
(NHS) around £50 million a year for preparation and
a similar amount for attendance time [23]. Whether this
substantial investment is justified, however, is unknown
and has not been previously considered. The aim,
therefore, of this paper was to systematically summarise
economic studies of MDT working in secondary cancer
and non-cancer care.Methods
Criteria for considering studies for this review
Types of studies
We reviewed economic evaluations of MDT working
compared to no MDT in the provision of secondary care
which includes hospital-based and community-based
care (Table 1). The types of study designs eligible for
inclusion were randomised controlled trials (RCTs),
cohort, case–control, before and after, cross-sectional,
and decision analysis modelling studies.
Types of participants
We included studies which enrolled people with any
disease type, receiving secondary care and we classified
these as cancer and non-cancer.
Types of interventions
MDTs were defined by evidence of both of the following
characteristics:
1. Team members from a minimum of two disciplines
making decisions;
2. Regular team meetings to discuss diagnosis,
treatment and/or patient management, occurring at
a physical location or by teleconferencing.
Where team members came from different grades
within one discipline, this was considered to represent a
single discipline (e.g. a consultant surgeon and a specialist
surgical registrar were counted as one discipline).
Studies that evaluated MDT decision making at the
patient bedside during ward rounds were excluded
because we felt that they were substantially different from
the type of meeting room based MDT work advocated in
recent policy initiatives (e.g. for cancer services) [6,27].
The key differences between the two are that meeting
room based MDTs require a coordinator, and include a
systematic review of information about the patient
without the patients’ input or interruptions. If a paper
did not state whether the MDT meeting was ward-based
or meeting room based, this was inferred from the
description of the meeting.
Types of outcome measures
Full economic evaluations (i.e. cost-effectiveness analysis,
cost-utility analysis, cost-benefit analysis and cost-
consequences analysis) [28] were considered for inclusion.
Types of costs
We included studies that reported on the costs of
supporting an MDT meeting or the subsequent direct
medical costs of care, non-medical costs (e.g. patient
travel), or indirect costs (e.g. productivity losses). The
costs of supporting an MDT typically include the costs of
Table 1 Inclusion and exclusion criteria for systematic review on cost-effectiveness of MDT working
Inclusion criteria Exclusion criteria
Studies comparing MDT care with no MDT care Studies that are not comparative i.e. focus on MDT care only
Secondary care services i.e. hospital-based or community-based Primary care
Study design – RCT, cohort, case–control, before and after, cross-sectional studies,
or modelling studies
Ecological studies, case reports
Applied study (i.e. studies generating primary data or modelling of secondary data) Methodological and general articles, expert opinion, letters
and abstracts
Population – persons diagnosed with any diseases
Study setting – any country
MDTs are defined as: Multidisciplinary ward rounds
a) Team members from a minimum of two disciplines making decisions; and
b) Regular team meetings to discuss diagnosis, treatment and/or patient management,
occurring at a physical location or by tele-conferencing
Outcomes - health outcomes which are relevant to the disease being investigated
Costs – average costs of organising MDT meetings, average cost per patient treated,
or incremental cost effectiveness ratios
Journal articles, grey literature Books
English language Foreign languages
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the latter could include travel expenses, or costs of tele-
conferencing, as well as administrative support provided
by a team coordinator.Search methods for identification of studies
We searched the databases EMBASE and MEDLINE
(both via the Ovid interface), NHS EED, CINAHL,
EconLit, Cochrane Library, and NHS HMIC for relevant
publications published from the date of inception of
each database to December 2011. Grey literature was
identified through the NHS HMIC database as well as
based on specialised knowledge of one of the authors
(JMB). The search strategy consisted of combinations of
free text and MeSH terms related to the economic
evaluation of an MDT (see Appendix 1). The search
included journal articles and grey literature published in
the English language. Reference lists from included
studies and other relevant publications, including reviews,
were manually checked for citations missed by the
electronic search.Data collection and analysis
Selection of studies
Initially, one author (KMK) selected reports fulfilling the
first inclusion criterion (see Table 1) of this review based
on title and abstract. Full articles of possibly relevant
studies were retrieved for more detailed evaluation. A final
selection of included studies was decided by discussion
with the whole team.Data extraction
A data extraction template, developed using the guidelines
provided by the Centre for Reviews and Dissemination
[29], was used to extract the following data alongside the
critical appraisal of original studies: country of investiga-
tion; objective of the study; study intervention and
comparator; study design and setting; target population
characteristics; sources and quality of clinical data, if
applicable; sources and quality of cost data; methods for
dealing with uncertainty; and study results. The following
data detailing the characteristics of MDT meetings
were also extracted: frequency of meetings, number of
disciplines contributing, meeting venue, description of
leadership style, method of dissemination of decision,
and administrative support. Two authors (KMK, SS)
independently extracted data. All discrepancies were
reviewed and consensus achieved by discussion.
Due to the varied nature of the studies, we provide a
narrative summary of the study results for our review
rather than a formal meta-analysis of results.Methodological quality assessment
The methodological quality of the included studies was
assessed using the Consensus on Health Economic
Criteria (CHEC-list), a 19-item assessment tool [30]. The
CHEC-list represents a minimum set of methodological
criteria that address aspects of the internal and external
validity of individual economic evaluation studies. For
each criterion, a study received a ‘yes’ if it had sufficiently
addressed that aspect of the study, and a ‘no’ if it had not.
Two authors (KMK, FEC) independently evaluated the
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the use of the CHEC-list. Disagreement was resolved by
discussion.
The six CHEC-list criteria that are regarded as most
important in assessing risk of bias are appropriate choice
of an time horizon, measurement of costs, valuation of
costs, measurement of outcomes, valuation of outcomes,
and discounting of future costs and outcomes [31].
Therefore, the risk of bias among the included studies
would be high if the number of studies that fulfilled
these six criteria is low.
Results
Overview
Our electronic literature search identified 1,788 articles.
After a detailed review of 63 articles, 15 were included
in the final analysis (Figure 1) [32-46]. Eleven were based
on RCTs, [32,34,36,38-41,43-46] most commonly performed
in diseases of older people [34,39,40,44] (Table 2). Only two
studies evaluated MDT working in cancer care [35,37],
and none were conducted in the UK. The majority of
studies only included costs borne by the health care payer.
No studies estimated the full cost of administering,
preparing for and attending an MDT meeting.
Methodological quality assessment
Only four of the nineteen criteria (i.e. research question
posed in answerable form, appropriate economic study
design, appropriate time horizon, and identification of
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Figure 1 Studies selection process.studies (Table 3). The choice of an appropriate time
horizon is one of the six CHEC-list criteria that are
regarded as important in assessing risk of bias [31].
None of the other five criteria were fulfilled by all the
studies. In particular, the criteria of appropriate valuation
of costs and appropriate discounting of future costs were
met by very few studies – four and two respectively. The
reasons for a high number of studies not meeting the
criterion of appropriate valuation of costs were either a
lack of information on the method of valuation, the
reference year, or the use of a top-down approach in the
apportionment of costs a. There were four studies in the
review that should have discounted future costs and
outcomes because their analytic horizon was more than
a year. However, only two [42,43] stated that discounting
was undertaken in the analysis. Therefore, given that five
of the six criteria that had an impact on the assessment of
risk of bias were not met by all studies, there is a relatively
high risk of bias in the results of the reviewed studies.Characteristics of MDT meetings
The amount of detail provided about MDT meetings
varied. Twelve papers reported the frequency of meetings
which varied from daily to once every three months
(Table 4). The average number of disciplines in each MDT
was 5 ranging from 2 to 9. Only one study stated the
venue of the MDT meeting [44]. Five of the studies gave
details of who led the meetings. No information was
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Table 2 Summary of key characteristics of included
studies (n = 15)
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Diagnosis and treatment/care plan 4
* 1 study had both inpatient and outpatient care.
Table 3 Number of studies fulfilling each Consensus on
Health Economic Criteria (CHEC-list) quality criterion
CHEC-list quality criteria Number of studies
fulfilling criterion
1. Is the study population clearly described? 12
2. Are competing alternatives clearly described? 14
3. Is a well-defined research question posed in
answerable form?
15
4. Is the economic study design appropriate to
the stated objective?
15
5. Is the chosen time horizon appropriate in order
to include relevant costs and consequences?
15
6. Is the actual perspective chosen appropriate? 3
7. Are all important and relevant costs for each
alternative identified?
0
8. Are all costs measured appropriately in physical
units?
11
9. Are costs valued appropriately? 4
10. Are all important and relevant outcomes for
each alternative identified?
15
11. Are all outcomes measured appropriately? 13
12. Are outcomes valued appropriately? 13
13. Is an incremental analysis of costs and
outcomes of alternatives performed?
3
14. Are all future costs and outcomes discounted
appropriately?
2
15. Are all important variables, whose values are
uncertain, appropriately subjected to sensitivity
analysis?
3
16. Do the conclusions follow from the data
reported?
9
17. Does the study discuss the generalizability of
the results to other settings and patient/client
groups?
2
18. Does the article indicate there is no potential
conflict of interest of study researcher(s) and
funder(s)?
4
19. Are ethical and distributional issues discussed
appropriately?
0
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reported how the MDT decisions were disseminated.
RCTs assessing cost-effectiveness of MDTs in non-cancer
care
There were 11 RCTs that reported full economic evalua-
tions of MDT care (Table 5). Four evaluated geriatric
care, and the results were mixed. One RCT found that
MDT directed care resulted in lower costs as well as
improvement in some outcome measures. This studyincluded two sites, and it was found that for one of the
sites, total costs were lower by approximately 15%, and
there were fewer complications during hospitalisation
(between 3 to 12 fewer for different types of complica-
tions) [34]. However, two other RCTs of geriatric care
concluded that there was no evidence of differences in
costs or outcomes between MDT and no MDT care
[39,44]. The fourth RCT in geriatric care showed that
MDT care was associated with higher costs because the
cost of implementing MDT care b for 6 months offset
the reduction in medication costs, but there was no
evidence of differences in functional status and survival
between the two groups [40].
Similarly, there were inconsistent results from two
RCTs of MDT care for patients suffering from heart











Collard et al., 1985 Twice a week 6 Not stated Not stated Not stated Not stated
Williams et al., 1987 Daily 6 Outpatient clinic Not stated Not stated Care plan
Timpka et al., 1997 Weekly 3 Not stated Physicians Not stated Not stated
Fader et al., 1999 Biweekly 9 Not stated Not stated Not stated Treatment plan
Kominski et al., 2001 At least once every
3 months
8 Not stated Not stated Not stated Treatment plan
Capomolla et al., 2002 Not stated 6 Not stated Not stated Not stated A report
Kasper et al., 2002 Weekly 3 Not stated Not stated Not stated Treatment plan
Carling et al., 2003 Not stated 2 Not stated Infectious disease physician Not stated Pro forma placed in
front of patient’s chart
Van Den Hout et al., 2003 Weekly 5 Not stated Not stated Not stated Not stated
Rabow et al., 2004 Regularly 8 Not stated Team Physician Not stated Care plan
Yagura et al., 2005 Weekly 7 Not stated Not stated Not stated Discharge plan
Gade et al., 2008 Daily 4 Not stated Not stated Not stated Palliative care plan
Wolfs et al., 2009 Weekly 6 Not stated Not stated Not stated Care plan
Hagiwara et al., 2011 Twice per week 4 Not stated Hemato-oncologist Not stated Care plan
Pope et al., 2011 Not stated 3 Not stated Modified Delphi method Not stated Not stated
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effective with an incremental cost-effectiveness ratio
of US$1,068 per Quality Adjusted Life Year (QALY)
(£663/QALY, £1 = US$1.61, rate as at 20 April 2012)
[32]. However, the other RCT showed that there was no
evidence of a real cost difference but quality of life
improved when comparing MDTand no-MDTcare [38].
Two RCTs evaluated MDT care amongst patients with
terminal conditions; the results were mixed. One reported
that costs were lower for the MDT group by about 30%,
but there was no evidence of any differences in measures
of symptom control, survival, and quality of life between
the MDT and no MDT groups [36]. In contrast, the other
study showed that there was no evidence of a real cost
difference but some outcome measures such as dyspnea,
anxiety, spiritual well-being, improved when comparing
MDTand no-MDTcare [41].
The last three RCTs, each of people with a different
disease, also showed varied results. One study relating to
patients with mental health problems found that MDT
care was cost-effective with an incremental cost effective-
ness ratio of €1,267/QALY (£1,039/QALY, £1 = €1.22, rate
as at 20 April 2012) [45]. However, a RCT concerning
stroke patients concluded that there was no evidence
of real cost or outcome measures differences [46].
Furthermore, in a study that investigated the impact
of MDT care versus no MDT care among patients
diagnosed with rheumatoid arthritis, there was no
evidence of differences in outcome measures but costs
were higher in the MDT care group by approximately 30%
to 50% [43].Other study designs assessing cost-effectiveness of MDTs
in non-cancer care
A prospective cohort study based in Sweden which
considered the effect of MDT on vocational activity
among patients with chronic minor diseases and long-term
absence from working life, reported a total discounted cost
of 7.2 million SEK (£684,410, £1 = 10.52 SEK, rate as at 20
April 2012), total benefits of 35.1 million SEK (£3.3
million), and hence, a positive cost-benefit ratio of 4.9
[42]. No estimate for cost per person was provided. In
addition, a ‘before and after’ study found that the rate of
infection per 1000 patient days after the implementation
of MDT antibiotic management care fell by between 25%
to 70% and costs decreased by about 30% [33].Studies assessing cost-effectiveness of MDTs in cancer care
There were two non-randomised studies that reported
results of MDTs in cancer care (Table 5). In a retrospective
cohort study of MDT versus no MDT care for patients
with malignant melanoma, the costs of health care were
33% to 50% lower in patients whose management decisions
were made by an MDT [35]. However, there was no
evidence of any differences in wound complication and
5-year survival rates. Hagiwara et al. (2011) [37] reported
clinical outcomes before and after the introduction of
a multidisciplinary nutritional team for patients with
haematologic malignancies. It was found that incidences
of hepatic complications, hyperglycemia, and central
venous catheter infection were lower in the ‘after’ group
than in the ‘before’ group, and costs fell by about 20%.
Table 5 Details of included studies (n = 15)
Authors, date,
and country
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Table 5 Details of included studies (n = 15) (Continued)
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Summary of findings
We identified fifteen primary studies on the cost-
effectiveness of MDT decision making in secondary care,
of which only two concerned cancer and the others
covered a wide range of disease types. The characteristics
of MDT meetings were diverse. The existing evidence was
limited and there was a relatively high risk of bias amongst
the studies. Whilst both studies relating to cancer care
showed that MDTs were associated with lower costs and
better outcomes or outcomes comparable to no MDT
care, neither study was a RCT. The results from eleven
RCTs assessing the cost-effectiveness of MDTs in
non-cancer care were very varied. Only three of these
showed that MDT working in secondary care had a
positive effect on outcomes and costs. However, the
degree of this positive impact varied. Moreover, the
positive impact of MDT on some costs components
might be offset by the full cost of administering, preparing
for and attending an MDT meeting, for which no
estimates were reported in the included studies. There-
fore, based on existing evidence, it is not possible to
determine if MDT working is cost-effective or not in
secondary cancer and non-cancer care.
Strengths and weaknesses of this systematic review
To our knowledge, we conducted the first systematic
review on the cost-effectiveness of MDT working in
secondary care, and we explicitly attempted to capture
all types of costs, especially the significant costs of
supporting MDT working. The limitations of this review
need to be borne in mind. Firstly, as with any systematic
review, publication bias might be a problem if studies
with null findings have not been published. Secondly,
this review was not restricted to a particular country or
disease type. While this approach is valuable in describing
the available evidence from a wide perspective, it restricts
the comparability across studies. Given that the studies
were diverse, particularly in the type of care offered in the
comparison groups, the findings may not be applicable
across different healthcare settings where different
clinical practices and geographical constraints operate.
The operationalising of MDT may also differ in different
settings and together with the variability in reporting,
there may be studies that have been conceived as MDT,
but based on our interpretation, were not. However, we
tried to be inclusive in our definition of MDT working so
that we did not exclude potentially relevant studies.
Weaknesses of the evidence
We have identified four key weaknesses in the existing
literature on the cost-effectiveness of MDT working. First,
there was no standard definition or operationalisation of
MDT working evident in the literature. Most studies didnot provide key details of the MDT meeting venue,
leadership (i.e. who leads the meeting and or how are
decisions made), or administrative support. Without a
common definition or clear description of MDTs, it was
difficult to compare results between studies or draw
conclusions on the cost-effectiveness of MDT decision
making. Second, the full costs of administering, preparing
for and attending an MDT meeting were not estimated in
the included studies. Given that the MDT meeting is a key
feature of MDT working, the omission of the associated
costs in any cost-effectiveness analysis of MDT could lead
to an underestimation of costs, and hence bias in the
results. Third, the methodological quality assessment has
demonstrated that there was a relatively high risk of bias
amongst the studies. This meant that the reliability and
reproducibility of the included studies were compromised,
and the ability to determine conclusions from our
systematic review was restricted. Fourth, the available
evidence was limited so that it was not possible to draw
firm conclusions as to whether MDT working in cancer or
non-cancer care would lead to cost-effective care or not.
Comparison with other studies
In their review to determine the critical elements of
effective team-working in patient care teams, Bosch
et al. [47] concluded that current literature provided little
insight into the underlying mechanisms. They reported
results relating to costs and resource utilisation but not on
cost-effectiveness of MDTs. In comparison, our systematic
review focused specifically on full economic evaluations
of MDT working, and sought to include studies that
estimated the costs of supporting MDT working. In
another review examining the association between cancer
MDTs and survival, the authors also highlighted the lack
of a consistent definition of MDT [21]. This directly
hampers any investigation of its effectiveness and costs.
While none of the included studies in this review had
accounted for the full costs of administering, preparing
for and attending an MDT meeting, an audit conducted at
a large teaching hospital/cancer centre estimated the aver-
age annual cost of MDTs in salaries alone was about £1
million [48]. Time spent preparing for MDT meetings
could be considerable. A study examining the participation
of pathologists and radiologists in MDT meetings found
that the former spent about an average of 2.4 hours, and
the latter 2 hours in preparation [49]. Although our review
did not find evidence that MDT working is cost-effective
in cancer care, there appears to be a growing consensus
that telemedicine delivered MDT cancer meetings are
more cost-effective than ‘in-person’ meetings [50-53].
Future research
Based on the findings of our systematic review, we
propose that three issues need to be addressed in future
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ensure a clear definition of MDT working and detailed
reporting of its characteristics. In our systematic review,
we found that the description of the two key features of
MDT working was so vague that it was difficult to
determine whether MDT working had taken place or
not. We recommend that studies should provide the
characteristics of the MDT meeting as shown in
Table 4. Secondly, it is essential to estimate the full costs
of administering, preparing for and attending an MDT
meeting. Such attempts should take into account two
issues. One, all relevant costs should be identified. We
recommend that the following costs should be accounted
for: time spent by each team member in preparing for the
MDT meeting and this should include time spent by team
coordinator in providing administrative support to the
MDT meeting, time spent on travelling to and from
meetings by any team member who is located on a
different site than the meeting venue, costs of using tele-
conferencing if applicable, and time spent by each
member at each meeting. Two, these costs should be
measured as accurately as possible. The standard
methods used in health services research for workflow
assessments are work sampling, time efficiency, and
time-and-motion. The first two methods are less resource
intensive as compared to the third method but there is
evidence to show that the time-and-motion technique
may produce the most accurate results [54-56]. Thirdly, it
remains unclear what models of MDT are cost-effective in
secondary care. Therefore, future studies using strong
study designs should compare the cost-effectiveness of
different models or aspects of MDT working c. For this
to be performed accurately there is a need for agreement
in the clinical community about which outcomes would
be core in the evaluation of MDT working. Whilst
some clinical outcomes are important, the inclusion
of patient-centred outcomes and satisfaction of health
professionals as well as assessment of the quality of
decision-making and MDT decision-implementation may
also be important [2,57,58].
Policy implications
Without further research that addresses the three key
issues highlighted in the previous section, it would be
hard to make firm policy recommendations. The cost-
effectiveness of MDT working in secondary care is likely to
vary according to many factors, such as cost of supporting
MDT working, disease type, treatment selected, and
geographical location. The costs of supporting MDT
working are directly linked to factors that affect
management decisions of MDTs, such as inclusion of
time to prepare for MDTs into team-members’ job plans,
making team and leadership skills training available to
team-members, and systematic input from nursingpersonnel [59]. The commitment of resources to these
factors will differ across settings. Therefore, it is likely that
there is no ‘one-size-fits-all’ model of MDT working to
suit all diseases, treatment modalities and locations.
Conclusion
The widespread adoption of MDT working in cancer
and non-cancer care has occurred despite a lack of
evidence on cost-effectiveness. The available evidence is
limited and at relatively high risk of bias. It is not
possible to determine if MDT working in cancer and
non-cancer care is cost-effective or not. Further studies
aimed at understanding the key aspects of MDT working
that lead to cost-effective care, and the costs of supporting
MDT working are required.
Endnotes
a Costs can be derived by a bottom-up or top-down
approach. In a bottom-up approach, costs are determined
by examining individual utilisation. In a top-down
approach, costs are apportioned across individuals, and
this may be less accurate due to questionable assumptions
used in the apportionment of costs.
b Personal communication with the lead author has con-
firmed that these costs did not include the full costs of ad-
ministering, preparing for and attending an MDT meeting.
c As MDT working is now so prevalent in secondary care,
especially cancer care, it might not be possible to compare
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